文献速递哮喘

度普利尤单抗对2型哮喘呼出气一氧化氮、黏液栓及功能呼吸成像的影响(VESTIGE):随机双盲安慰剂对照4期试验

Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial.
PubMed 文献 · Lancet Respir Med · 2025-02-10

气道容积(s)iVaw变化差异未达显著。安全性与该药已知特征一致。

要点

  • 安全性与该药已知特征一致,无干预期间死亡报告。

核心结论

  • 度普利尤单抗可降低2型哮喘患者气道炎症和黏液栓、改善气道容积和气流,对应肺功能与哮喘控制改善。
  • 功能呼吸成像技术有潜力评估疾病负担、监测进展和评价治疗反应,辅助中重度2型哮喘的临床决策。

研究设计与样本

  • VESTIGE为随机、双盲、安慰剂对照4期试验,在14个国家72个研究站点或学术中心开展。
  • 纳入18-70岁医生诊断的控制不佳中重度2型哮喘成人患者,血嗜酸性粒细胞≥300 cells/μL且FeNO≥25 ppb,正使用中高剂量吸入糖皮质激素联合其他控制药物。
  • 患者按2:1随机分配接受加用度普利尤单抗300 mg皮下注射每2周一次或容积匹配安慰剂至第24周,随机按吸入糖皮质激素剂量水平和地区分层。
  • 主要终点为第24周FeNO浓度低于25 ppb的患者比例,以及第24周气道容积(s)iVaw在总肺容量下的百分比变化,均在意向治疗人群评估。

主要发现

  • 与研究干预相关的不良事件:度普利尤单抗组11/72(15%),安慰剂组4/37(11%);干预期间无死亡。

关键数值与推荐

  • 与研究干预相关不良事件发生率度普利尤单抗组15% vs 安慰剂组11%。

临床怎么用

  • 对于控制不佳的中重度2型哮喘(血嗜酸性粒细胞≥300 cells/μL且FeNO≥25 ppb),加用度普利尤单抗300 mg每2周一次可显著提高第24周FeNO<25 ppb的比例。
  • 功能呼吸成像可用于评估气道炎症、黏液栓及气道容积变化,辅助监测疾病进展和治疗反应。
  • 度普利尤单抗安全性与该药已知特征一致,相关不良事件发生率与安慰剂相近。

局限性

  • 样本量较小(度普利尤单抗组72例,安慰剂组37例)。
  • 研究期限至第24周,未报告更长疗程数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Asthma is a respiratory disease characterised by chronic airway inflammation and mucus hypersecretion. VESTIGE used functional respiratory imaging to assess changes in airway structure and function, including mucus plugging, in response to dupilumab. METHODS: VESTIGE was a randomised, double-blind, placebo-controlled, phase 4 trial done at 72 research sites or academic centres in 14 countries. We recruited adult patients (aged 18-70 years) with physician-diagnosed, uncontrolled, moderate-to-severe type 2 asthma (blood eosinophil count ≥300 cells/μL and fractional exhaled nitric oxide [FeNO] ≥25 parts per billion [ppb]) being treated with medium-dose to high-dose inhaled corticosteroids combined with other controller medications. Patients were randomly assigned (2:1; block size of 6) via interactive voice-web response technology to receive add-on dupilumab 300 mg subcutaneously once every 2 weeks or volume-matched placebo up to week 24. Randomisation was stratified by inhaled corticosteroids dose level and region (eastern Europe vs the rest of the world). Participants and investigators, including those assessing outcomes, were masked to group assignment. The primary endpoints were the proportion of patients with a FeNO concentration below 25 ppb at week 24, and percentage change from baseline to week 24 in airway volumes (specific regional airway volumes corrected for lung volume, [s]iVaw) at total lung capacity (TLC), both assessed in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study drug or placebo. The trial is registered with ClinicalTrials.gov, NCT04400318, and is completed. FINDINGS: Patient recruitment occurred from July 18, 2020, to Jan 6, 2023. Patients (mean age 50·4 years [SD 12·6]; 68 [62%] female and 41 [38%] male) were randomly assigned to receive dupilumab 300 mg (n=72) or placebo (n=37). At week 24, patients in the dupilumab group were significantly more likely than those in the placebo group to have a FeNO concentration below 25 ppb (41 [57%] of 72 patients vs four [11%] of 37; odds ratio: 9·8 [95% CI 3·1 to 30·8]; p<0·001). Treatment with dupilumab versus placebo led to a numerical increase in (s)iVaw at TLC from baseline to week 24, although the difference was not significant (least squares [LS] mean percentage change from baseline to week 24: 19·7% [SE 8·1] for dupilumab and -2·0% [11·5] for placebo; LS mean difference vs placebo: 21·8% [95% CI -7·7 to 51·3]; p=0·14). Safety was consistent with the reported safety profile for dupilumab. Treatment-emergent adverse events related to study intervention were reported in 11 (15%) of 72 patients who received dupilumab and four (11%) of 37 who received placebo; no deaths occurred during the intervention period. INTERPRETATION: The full results of this study indicate that dupilumab reduced airway inflammation and mucus plugging, and improved airway volume and flow, corresponding to improved lung function and asthma control. This study highlights the potential of imaging technology to assess disease burden, monitor progression, and evaluate therapeutic responses, which can provide valuable insights to guide clinical decision making for patients with uncontrolled, moderate-to-severe type 2 asthma. FUNDING: Sanofi and Regeneron Pharmaceuticals.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Castro M, Papi A, Porsbjerg C, et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025. PMID: 39947221. doi:10.1016/S2213-2600(24)00362-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。